GLENMARKBSEGLENMARK PHARMACEUTICALS· Pharmaceuticals & BiotechnologyHighNeutral
Announced Fri, 31 Jul, 2026 · 18:38 IST

Glenmark Q1 FY27 results: revenue up 23%, PAT jumps 10x on consol basis

Revenue Growth 20pctPat Growth 25pctExceptional ItemResults View source PDFExplain this filing

GLENMARK · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-0.8%Reaction day
₹2248.00
prior close
₹2256.40
announcement price
After-mkt
timing
Nifty Midcap 150market+1.2%-2.0% vs market
Pharmaceuticals peers, median of 163sector+1.0%-1.8% vs sector

On the reaction day the stock moved 2.0 pts less than Nifty Midcap 150 and 1.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-1.9
10m
-2.1
15m
-2.7
30m
-3.4
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-0.8+1.2-2.0+1.0-1.8
Next day
-1.4+0.9-2.3+0.8-2.2
2d
+0.5+1.1-0.6+0.2+0.3
3d
+1.0+0.7+0.2+0.7+0.3
4d
+1.6+1.0+0.7+1.4+0.3
5d
+0.1+1.4-1.3+1.3-1.2
1w
+1.6+1.7-0.0+1.5+0.1
15d
+6.4+1.2+5.1+0.8+5.5
1m
+9.4+0.4+9.0+1.6+7.8
2m
+2.1-6.0+8.1+1.5+0.6
3m
—————
UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 163Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved Q1 FY27 results (quarter ended June 30, 2026). Consolidated revenue rose 23% to Rs 40,185 mn from Rs 32,644 mn YoY. Consolidated PAT surged to Rs 4,828 mn vs Rs 470 mn. Standalone PAT was Rs 7,356 mn vs Rs 3,302 mn, boosted by a Rs 2,230 mn exceptional gain from Nebulizer brand transfer to subsidiary. Standalone net sales grew 7.5% to Rs 23,425 mn. Auditor gave unmodified review. Dividend record date Aug 31, AGM Sep 11, 2026.

Likely market impact

Strong quarter with consolidated revenue up 23% and PAT nearly 10x. Standalone lifted by exceptional gain. Watch dividend record date Aug 31.